Retatrutide
Triple agonist — GIP, GLP-1, and glucagon receptor
Quick Answer
An investigational synthetic peptide designed to activate three metabolic-hormone receptor pathways simultaneously, one step beyond the dual-agonist mechanism of tirzepatide.
Why People Are Interested
Often described as "the next GLP-1 breakthrough" — triple-pathway agonism (GIP + GLP-1 + glucagon) has reported some of the largest weight-loss percentages seen in early trials of any compound in this class, making it one of the most-discussed investigational peptides in recent memory.
What People Hope It May Do
That adding the glucagon-receptor pathway meaningfully increases energy expenditure on top of the appetite and insulin effects already seen with dual agonists — an intriguing hypothesis, not yet an established clinical outcome. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)
Potential / Research Areas
Weight-loss magnitude compared to dual and single-pathway agonists
Effects on metabolic-associated fatty liver disease
Cardiometabolic risk factor changes
Safety and tolerability across dose ranges
How It May Work
Combined GIP/GLP-1/glucagon receptor agonism is hypothesized to increase energy expenditure (via the added glucagon-receptor component) in addition to the appetite and insulin effects seen with GIP/GLP-1 agonists — this remains a research hypothesis under active investigation, not an established mechanism of clinical benefit.
What Human Research Shows
Limited to Phase 2 (and, as of last review, progressing toward/through Phase 3) clinical trial data — smaller and earlier-stage than the semaglutide/tirzepatide evidence base. Trial phase status changes quickly, so this should always be checked against clinicaltrials.gov directly.
What Preclinical Research Shows
Standard preclinical pharmacology package consistent with an investigational drug in active clinical development.
Six independent readings, not one score. This reflects the volume and stage of research and discussion — it is not a rating of safety or effectiveness.
"Real-World Interest" and "Research Momentum" reflect the volume of public discussion and research activity Element Health Labs has observed — an editorial judgment, not a measured statistic, and not a claim about clinical significance. Anecdotal popularity is not evidence of effectiveness.
What People Report
What Experts Are Saying
Curated commentary specific to Retatrutide is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.
Clinical Trials
For the current, authoritative list of registered trials involving Retatrutide, search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.
Potential Risks & Side Effects
Early trial data has reported a gastrointestinal side-effect pattern similar to other incretin-pathway agents; full safety profile is still being established through ongoing trials. No individualized safety guidance should ever be given for an unapproved investigational compound.
Regulatory Status
Not FDA-approved. Investigational — in the manufacturer's (Eli Lilly) clinical trial pipeline. Not available as an approved prescription product; any consumer-facing sale of this compound for human use would be outside FDA approval.
Recent development (2026-09-10, re-verified): TRIUMPH-3, a Phase 3 trial in adults with severe obesity (BMI ≥35) and established cardiovascular disease (NCT05882045, ClinicalTrials.gov, officially registered — confirmed COMPLETED, primary completion 2026-04-16, primary outcome "Percent Change from Baseline in Body Weight" at Week 80, matching the trial's own registered design), reached completion and Lilly reported topline results (~22.6% mean body weight loss, ~56 lbs, at 80 weeks) in press communications. As of this review, ClinicalTrials.gov's own results-posting field for this trial still shows no results posted (hasResults: false), and no peer-reviewed publication has been identified — so these specific efficacy figures are company-reported topline data only, not yet independently verifiable against an official trial-results posting or a peer-reviewed paper. They should always be attributed explicitly as company-reported topline, never presented as FDA-confirmed or peer-reviewed. Separately, Lilly opened a narrow pre-approval expanded-access program in August 2026 for patients with BMI ≥35, two or more serious obesity-related complications, and no ability to join an ongoing trial (NCT07629401, ClinicalTrials.gov, officially registered, confirmed directly — a distinct program from TRIUMPH-3, not a route to the drug's general efficacy data). Lilly has stated a plan to file for FDA approval in Q1 2027 — this is the company's own stated plan, not an FDA commitment or timeline, and should never be described as an approval date.
What We Still Don't Know
Full Phase 3 results, a real-world safety profile at scale, and whether the added mechanism actually outperforms tirzepatide in ways that matter for patients — all still being determined by ongoing trials.
Limitations of Evidence
Early-stage relative to approved GLP-1/GIP drugs; smaller sample sizes; long-term safety data does not yet exist at the scale available for approved products.
Keep Researching
- Search ClinicalTrials.gov for Retatrutide
- Expert & Creator Library
- This Week in Peptides
- Understanding Your Bloodwork
- Related peptides:
Last reviewed: 2026-09-10 — TRIUMPH-3 and the expanded-access program both re-verified directly against their official ClinicalTrials.gov registrations; efficacy figures confirmed as company-reported topline only, not yet independently verifiable.